Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer

　　2024年1月12日，在《Frontiers in Oncology》上发表的论文，标题为：“Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer”

　　使用缔一生物国内总代理的德国MB Venor GeM-qEP kit from Minerva Biolabs。